CD8A and melanoma: In preclinical mouse models, our recent unpublished data demonstrate the detection of CD8+ T-cell responses to homocitrullinated peptides that can provide tumour therapy against the aggressive murine B16 melanoma model suggesting that homocitrullinated peptides are also recognized by CD8 T cells in the tumour microenvironment.